These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 28604110)

  • 1. Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma.
    de Rosamel L; Blanc JF
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):175-190. PubMed ID: 28604110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
    Kim DY
    Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral chemotherapy for the treatment of hepatocellular carcinoma.
    Yamamoto S; Kondo S
    Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
    Oikonomopoulos G; Aravind P; Sarker D
    Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
    Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.
    da Fonseca LG; Reig M; Bruix J
    Clin Liver Dis; 2020 Nov; 24(4):719-737. PubMed ID: 33012455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel drugs in clinical development for hepatocellular carcinoma.
    Waidmann O; Trojan J
    Expert Opin Investig Drugs; 2015; 24(8):1075-82. PubMed ID: 26108356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of tyrosine kinase inhibitors in hepatocellular carcinoma.
    Kim S; Abou-Alfa GK
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):36-41. PubMed ID: 25000314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs for the treatment of hepatocellular carcinoma.
    Ayoub WS; Jones PD; Yang JD; Martin P
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):141-149. PubMed ID: 35642526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape.
    Mody K; Abou-Alfa GK
    Curr Treat Options Oncol; 2019 Jan; 20(2):3. PubMed ID: 30635732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tivantinib: critical review with a focus on hepatocellular carcinoma.
    Rota Caremoli E; Labianca R
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1563-74. PubMed ID: 25307444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies.
    Sun W; Cabrera R
    J Gastrointest Cancer; 2018 Jun; 49(2):107-115. PubMed ID: 29453759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
    Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma.
    Ho HK; Chua BT; Wong W; Lim KS; Teo V; Ong HT; Chen X; Zhang W; Hui KM; Go ML; Ullrich A
    Mol Oncol; 2014 Oct; 8(7):1266-77. PubMed ID: 24839937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma.
    Huynh H; Ong RW; Li PY; Lee SS; Yang S; Chong LW; Luu DA; Jong CT; Lam IW
    Anticancer Agents Med Chem; 2011 Jul; 11(6):560-75. PubMed ID: 21554207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
    Brizzi MP; Pignataro D; Tampellini M; Scagliotti GV; Di Maio M
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1053-62. PubMed ID: 27548441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists.
    Lee SJ; Lim HY
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):191-200. PubMed ID: 28506080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
    Rimassa L; Pressiani T; Personeni N; Santoro A
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MET inhibitors for treatment of advanced hepatocellular carcinoma: A review.
    Qi XS; Guo XZ; Han GH; Li HY; Chen J
    World J Gastroenterol; 2015 May; 21(18):5445-53. PubMed ID: 25987766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.